clinical trial · NCT06887738
Study of NM8074 in Patients with Dermatomyositis (DM)
DermatomyositisNM8074
brief summary
This is a Phase II, open-label, multicenter study to evaluate the safety and efficacy of NM8074 administered via intravenous infusion in patients with Dermatomyositis (DM).
started
Jun 1, 2026
primary completion
Nov 1, 2027
completion
Dec 1, 2028
last updated
Mar 25, 2025
detailed description
The Proposed Study, NM8074-DM-701 will enroll a planned number of eight (8) DM subjects, with the potential to enroll more patients. The total duration of the study for all subjects will include a 30-day screening period, dosing for a 12-week Treatment Period, followed by an observation period of 6-weeks. All subjects will be administered 20 mg/kg of NM8074 intravenously every week for a total of 12 doses from Day 1 to Day 78 of the Treatment Period.
official title
A Proof-of-Concept Phase II, Open-Label Study of NM8074 in Patients with Dermatomyositis (DM)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol